Ju Tongzhong, Cummings Richard D
Department of Biochemistry and Molecular Biology and the Oklahoma Center for Medical Glycobiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16613-8. doi: 10.1073/pnas.262438199. Epub 2002 Dec 3.
Human core 1 beta3-galactosyltransferase (C1beta3Gal-T) generates the core 1 O-glycan Galbeta1-3GalNAcalpha1-SerThr (T antigen), which is a precursor for many extended O-glycans in animal glycoproteins. We report here that C1beta3Gal-T activity requires expression of a molecular chaperone designated Cosmc (core 1 beta3-Gal-T-specific molecular chaperone). The human Cosmc gene is X-linked (Xq23), and its cDNA predicts a 318-aa transmembrane protein ( approximately 36.4 kDa) with type II membrane topology. The human lymphoblastoid T cell line Jurkat, which lacks C1beta3Gal-T activity and expresses the Tn antigen GalNAcalpha1-SerThr, contains a normal gene and mRNA encoding C1beta3Gal-T, but contains a mutated Cosmc with a deletion introducing a premature stop codon. Expression of Cosmc cDNA in Jurkat cells restored C1beta3Gal-T activity and T antigen expression. Without Cosmc, the C1beta3Gal-T is targeted to proteasomes. Expression of active C1beta3Gal-T in Hi-5 insect cells requires coexpression of Cosmc. Overexpression of active C1beta3Gal-T in mammalian cell lines also requires coexpression of Cosmc, indicating that endogenous Cosmc may be limiting. A small portion of C1beta3Gal-T copurifies with Cosmc from cell extracts, demonstrating physical association of the proteins. These results indicate that Cosmc acts as a specific molecular chaperone in assisting the foldingstability of C1beta3Gal-T. The identification of Cosmc, a uniquely specific molecular chaperone required for a glycosyltransferase expression in mammalian cells, may shed light on the molecular basis of acquired human diseases involving altered O-glycosylation, such as IgA nephropathy, Tn syndrome, Henoch-Schönlein purpura, and malignant transformation, all of which are associated with a deficiency of C1beta3Gal-T activity.
人核心1β3-半乳糖基转移酶(C1β3Gal-T)可生成核心1 O-聚糖Galβ1-3GalNAcα1-Ser/Thr(T抗原),它是动物糖蛋白中许多延伸O-聚糖的前体。我们在此报告,C1β3Gal-T活性需要一种名为Cosmc(核心1β3-半乳糖基转移酶特异性分子伴侣)的分子伴侣的表达。人Cosmc基因位于X染色体上(Xq23),其cDNA预测为一种具有II型膜拓扑结构的318个氨基酸的跨膜蛋白(约36.4 kDa)。人淋巴母细胞T细胞系Jurkat缺乏C1β3Gal-T活性并表达Tn抗原GalNAcα1-Ser/Thr,它含有一个正常的编码C1β3Gal-T的基因和mRNA,但含有一个发生突变的Cosmc,该突变导致一个提前的终止密码子。在Jurkat细胞中表达Cosmc cDNA可恢复C1β3Gal-T活性和T抗原表达。没有Cosmc时,C1β3Gal-T会被靶向蛋白酶体。在Hi-5昆虫细胞中表达活性C1β3Gal-T需要共表达Cosmc。在哺乳动物细胞系中过表达活性C1β3Gal-T也需要共表达Cosmc,这表明内源性Cosmc可能是有限的。一小部分C1β3Gal-T可从细胞提取物中与Cosmc共纯化,证明了这两种蛋白质的物理结合。这些结果表明,Cosmc作为一种特异性分子伴侣,协助C1β3Gal-T的折叠/稳定性。Cosmc的鉴定,即哺乳动物细胞中糖基转移酶表达所需的一种独特的特异性分子伴侣,可能为涉及O-糖基化改变的获得性人类疾病的分子基础提供线索,如IgA肾病、Tn综合征、过敏性紫癜和恶性转化,所有这些都与C1β3Gal-T活性缺乏有关。